Metin Ilke @MetinIlke: "📉 Novo Nordisk $NVO ..."

United Kingdom

📉 Novo Nordisk $NVO (Novo-Nordisk A/S SPONS ADR) is down — temporary setback or start of a correction? Novo Nordisk stock fell this week after a mix of: 🇺🇸 Senate pressure on GLP-1 pricing in the U.S. (potential price caps or negotiation) 💉 Demand concerns due to ongoing shortages of Ozempic and Wegovy 📈 Stretched valuation after a long bull run (PE ratio remains high even after the dip) 🧬 Competition from Eli Lilly $LLY (Eli Lilly & Co) , now rolling out new obesity and diabetes drugs with strong data Yet, long-term bulls point out: 🌍 Still dominant in GLP-1 therapy globally 💰 Massive pricing power in Europe and emerging markets 🧪 Pipeline includes oral semaglutide, NASH drugs, and cardiometabolic combos 💎 Strong fundamentals, cash-rich, high margins 🤔 What do you think? Will Novo Nordisk bounce back in the short term? 1️⃣ Yes — this is a healthy pullback in a long-term uptrend 2️⃣ No — competition + regulation will weigh it down 3️⃣ Unclear — watching for next earnings report 4️⃣ I sold / taking profits here 💬 Let me know your reasoning in replies! $UNH (UnitedHealth) $VOO (Vanguard S&P 500 ETF) $SPY (SPDR S&P 500 ETF) $SPX500 $QQQ (Invesco QQQ) $NSDQ100

1️⃣ Yes

100.00%

2️⃣ No

100.00%

3️⃣ Unclear

100.00%

4️⃣ I sold / taking profits

100.00%